This company has been marked as potentially delisted and may not be actively trading. NASDAQ:RTRX Travere Therapeutics (RTRX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisNews and TrendsOwnership About Travere Therapeutics Stock (NASDAQ:RTRX) Get Travere Therapeutics alerts:Sign Up Key Stats Today's Range$31.43▼$33.0850-Day Range$24.25▼$28.1852-Week Range$8.98▼$24.96Volume1.20 million shsAverage Volume412,277 shsMarket Capitalization$1.62 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA. Read More Receive RTRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RTRX Stock News HeadlinesTravere Therapeutics Outlook Brightens As Turnaround LoomsSeptember 8, 2026 | investors.comTravere Therapeutics (TVTX) Releases Q2 2026 Earnings: Revenue Growth but Net Loss NarrowsAugust 4, 2026 | quiverquant.comQThis 38 Dollar Fund Holds Every Major AI Stock and Pays WeeklyThe biggest AI stocks like Nvidia, CrowdStrike, and Palantir now trade for hundreds of dollars a share. One fund owns them all for just $38 a share. This fund distributes income every Thursday, with a 34 percent annualized distribution rate, even though none of the underlying AI stocks pay dividends on their own. Tim Plaehn breaks down exactly how the fund works in a free video presentation.September 12 at 1:00 AM | Investors Alley (Ad)Travere wins FSGS approval for FILSPARI, a milestone for holders including Armistice CapitalJuly 22, 2026 | msn.comIs Travere Therapeutics, Inc. (TVTX) A Good Stock To Buy Now?June 13, 2026 | finance.yahoo.comTravere Therapeutics analysts increase their forecasts following Q1 earningsMay 5, 2026 | msn.comTravere Therapeutics (TVTX) price target increased by 16.06% to 50.45April 28, 2026 | msn.comTravere Therapeutics sees its composite rating rise to 97April 15, 2026 | msn.comSee More Headlines RTRX Stock Analysis - Frequently Asked Questions How were Travere Therapeutics' earnings last quarter? Travere Therapeutics, Inc. (NASDAQ:RTRX) released its earnings results on Thursday, November, 5th. The biopharmaceutical company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.15. Travere Therapeutics had a negative trailing twelve-month return on equity of 36.38% and a negative net margin of 49.13%. Who are Travere Therapeutics' major shareholders? Top institutional investors of Travere Therapeutics include Walleye Capital LLC (0.08%) and Oppenheimer Asset Management Inc. (0.01%). View institutional ownership trends. What other stocks do shareholders of Travere Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Travere Therapeutics investors own include CVS Health (CVS), Bristol Myers Squibb (BMY), Gilead Sciences (GILD), Novavax (NVAX), TG Therapeutics (TGTX), Dynavax Technologies (DVAX) and Intercept Pharmaceuticals (ICPT). Company Calendar Last Earnings11/05/2020Today9/12/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RTRX CIK1438533 Webwww.retrophin.com Phone(888) 969-7879FaxN/AEmployees221Year FoundedN/AProfitability EPS (Trailing Twelve Months)($3.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$146.43 million Net Margins-49.13% Pretax MarginN/A Return on Equity-36.38% Return on Assets-14.90% Debt Debt-to-Equity Ratio0.66 Current Ratio7.23 Quick Ratio7.14 Sales & Book Value Annual Sales$175.34 million Price / Sales9.22 Cash FlowN/A Price / Cash FlowN/A Book Value$5.15 per share Price / Book6.15Miscellaneous Outstanding Shares51,052,000Free FloatN/AMarket Cap$1.62 billion OptionableNot Optionable Beta0.67 The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:RTRX) was last updated on 9/12/2026 by MarketBeat.com Staff. From Our PartnersThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredWhy the Treasury still prices gold at 42 dollars an ounceThe U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...Golden Portfolio | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredThis 38 Dollar Fund Holds Every Major AI Stock and Pays WeeklyThe biggest AI stocks like Nvidia, CrowdStrike, and Palantir now trade for hundreds of dollars a share. One fu...Investors Alley | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored17 Nobel Prize winners… one startling warningOn July 13, 17 Nobel laureates including Bernanke, Krugman, and Stiglitz signed an 88-word letter warning that...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RTRX Stock Alerts